Quarterly ResultMay 7, 2026, 04:04 PM
Voyager Therapeutics Q1 Cash $172M; VY1706 Clinical Entry H2 2026
AI Summary
Voyager Therapeutics reported its first quarter 2026 financial and operating results, highlighting significant pipeline advancements and a strong financial position. The company completed IND-enabling GLP toxicology for VY1706 and Neurocrine's NBIB-‘223, with both programs expected to enter clinical trials in the second half of 2026. Voyager ended Q1 2026 with $171.7 million in cash, providing a runway into 2028. The company also reported a net loss of $27.9 million and collaboration revenue of $2.6 million for the quarter.
Key Highlights
- VY1706 and NBIB-‘223 completed IND-enabling GLP toxicology studies.
- VY1706 is on track for first-in-human dosing in Alzheimer's disease patients in H2 2026.
- Neurocrine intends to initiate a clinical trial for NBIB-‘223 in Friedreich’s ataxia in H2 2026.
- Voyager Therapeutics ended Q1 2026 with $171.7 million in cash, cash equivalents, and marketable securities.
- The company expects its cash runway to extend into 2028.
- Net loss for Q1 2026 was $27.9 million, an improvement from $31.0 million in Q1 2025.
- Collaboration revenue for Q1 2026 was $2.6 million, down from $6.5 million in Q1 2025.
- Research and development expenses decreased to $24.6 million in Q1 2026 from $31.5 million in Q1 2025.